Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

<p>CELEBRATION, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) a rare disease therapeutics company, today announced it resubmitted its New Drug Application (NDA) for arimoclomol, an investigational therapeutic candidate for the treatment of Niemann-Pick disease type C (NPC) to the U.S. Food and Drug Administration (FDA) on December 22, 2023. Based […]</p>
<p>The post <a href="https://forextv.com/top-news/zevra-therapeutics-announces-resubmission-of-arimoclomol-new-drug-application-to-the-u-s-food-and-drug-administration/">Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>